PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPembrolizumab
Keytruda(pembrolizumab)
Keytruda (pembrolizumab) is an antibody pharmaceutical. Pembrolizumab was first approved as Keytruda on 2014-09-04. It is used to treat hodgkin disease, melanoma, microsatellite instability, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat endometrial neoplasms, hodgkin disease, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma amongst others. The pharmaceutical is active against programmed cell death protein 1.
Download report
Favorite
COVID-19
Drugs Approved for Childhood Cancers
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
genetic phenomenaD055614
Trade Name
FDA
EMA
Keytruda (discontinued: Keytruda)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pembrolizumab
Tradename
Proper name
Company
Number
Date
Products
KeytrudapembrolizumabMerck & CoN-125514 RX2015-01-15
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
keytrudaBiologic Licensing Application2024-09-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
urinary bladder neoplasms—D001749C67
hodgkin disease—D006689C81
melanoma—D008545—
urethral neoplasmsEFO_0003846D014523—
ureteral neoplasmsEFO_0003844D014516C66
squamous cell carcinoma—D002294—
microsatellite instability—D053842—
Agency Specific
FDA
EMA
Expiration
Code
pembrolizumab, Keytruda, Merck Sharp & Dohme LLC
2028-12-03Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF02: Pembrolizumab
HCPCS
Code
Description
J9271
Injection, pembrolizumab, 1 mg
Clinical
Clinical Trials
2492 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.020034162225538
Non-small-cell lung carcinomaD002289——22426095344521
NeoplasmsD009369—C8035622110117465
MelanomaD008545——16518229133333
Squamous cell carcinoma of head and neckD000077195——1031522019237
Squamous cell carcinomaD002294——801502318223
Colorectal neoplasmsD015179——9486818159
AdenocarcinomaD000230——52891324138
Pancreatic neoplasmsD010190EFO_0003860C25544911187
GlioblastomaD005909EFO_0000515—213011142
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175HP_0100526C34.9014319885—33382
Breast neoplasmsD001943EFO_0003869C5010514920—8237
Triple negative breast neoplasmsD064726——749613—4159
Renal cell carcinomaD002292EFO_0000376—737213—6131
RecurrenceD012008——40987—2127
LymphomaD008223—C85.960794—1121
Ovarian neoplasmsD010051EFO_0003893C5657694—2106
Head and neck neoplasmsD006258——457110—4106
Stomach neoplasmsD013274EFO_0003897C1656649—4102
Liver neoplasmsD008113EFO_1001513C22.0405110—1396
Show 70 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphomaD016393——1825———38
Non-hodgkin lymphomaD008228—C85.92321———34
Large b-cell lymphoma diffuseD016403—C83.31619———29
LeukemiaD007938—C951415——125
Castration-resistant prostatic neoplasmsD064129——1214———23
T-cell lymphomaD016399——917———21
Follicular lymphomaD008224—C821213———20
Thyroid neoplasmsD013964EFO_0003841—417———19
Myeloid leukemia acuteD015470—C92.01010———17
Myeloid leukemiaD007951—C9299———15
Show 194 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuroblastomaD009447EFO_0000621—2————2
RhabdomyosarcomaD012208——2————2
Lip neoplasmsD008048—C002————2
Intraductal carcinoma noninfiltratingD002285—D05.11———12
MedulloblastomaD008527——2————2
Myelomonocytic leukemia chronicD015477—C93.11————1
AnemiaD000740HP_0001903D64.91————1
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.21————1
Myelodysplastic-myeloproliferative diseasesD054437——1————1
Myeloid leukemia accelerated phaseD015465——1————1
Show 32 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyocarditisD009205—I51.4————33
Autoimmune diseasesD001327HP_0002960M30-M36————33
Heart diseasesD006331EFO_0003777I51.9————22
Human influenzaD007251EFO_0007328J11.1————22
Interstitial lung diseasesD017563HP_0006530J84.89————22
Cardiovascular diseasesD002318HP_0001626—————11
CardiomyopathiesD009202EFO_0000318I42————11
PericarditisD010493EFO_0007427I30————11
VasculitisD014657HP_0002633—————11
MyositisD009220EFO_0000783G72.49————11
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePembrolizumab
INNpembrolizumab
Description
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>5GGS:A,C|heavy chain QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAY MELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH >5GGS:B,D|light chain EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTIS SLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5B8C, 5DK3, 5GGS, 5JXE
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3137343
ChEBI ID—
PubChem CID—
DrugBankDB09037
UNII IDDPT0O3T46P (ChemIDplus, GSRS)
Target
Agency Approved
PDCD1
PDCD1
Organism
Homo sapiens
Gene name
PDCD1
Gene synonyms
PD1
NCBI Gene ID
5133
Protein name
programmed cell death protein 1
Protein synonyms
CD279, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2
Uniprot ID
Q8IX89
Mouse ortholog
Pdcd1 (18566)
programmed cell death protein 1 (Q02242)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Keytruda – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 66,480 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
61,728 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use